Pharmacy-tolvaptan
Ended Awarded Last action
- Contract number
- 36C26222F0060
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $146,494
Award facts
- Contract value 100% obligated
- $146,493.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $11,426 | |
| Funding Only Action | $11,426 | |
| Original award | $123,643 |
About this award
On October 1, 2021, the Department of Veterans Affairs, Veterans Integrated Service Network 22, awarded a delivery order valued at $146,493.98 to Otsuka America Pharmaceutical Inc. for the supply of Tolvaptan (brand name Jynarque), a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. This firm fixed-price delivery order, with an ultimate completion date of July 7, 2023, was issued without a set-aside designation and performed at the contractor's facility in Potomac, Maryland. The award is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), enabling the VA to procure this critical specialty medication through an established ordering mechanism.
This delivery order is issued under a larger Blanket Purchase Agreement valued at $83.3 million for Jynarque that Otsuka America Pharmaceutical Inc. maintains with the VA's National Acquisition Center, with a completion date of March 26, 2026. Otsuka America Pharmaceutical Inc., headquartered in Rockville, Maryland, is a for-profit pharmaceutical manufacturer that serves as a primary supplier of specialty pharmaceuticals to the VA Healthcare system across multiple Integrated Service Networks. The company's substantial federal contracting portfolio, including a $396 million Federal Supply Schedule contract for pharmaceuticals and hematology products, demonstrates its established capability to support the VA's mission of delivering specialized pharmaceutical treatments to veterans nationwide.
Quick answers
Who was awarded contract 36C26222F0060?
36C26222F0060 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on October 1, 2021.
How much is contract 36C26222F0060 worth?
The government has obligated $146,494 on 36C26222F0060.
Is contract 36C26222F0060 an order under another contract?
Yes. 36C26222F0060 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26222F0060 competed?
The extent of competition for 36C26222F0060 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award